Who
Laura Sepp-Lorenzino
Director
Company insider
Files Form 4 as: Director, Taysha Gene Therapies; Director, Lexeo Therapeutics; EVP, Chief Scientific Officer, Intellia Therapeutics.
In numbers
- Trades disclosed
- 63
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $19.3M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 3 Jun 2019
- Last trade
- 1 Jun 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 2 Jun 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —21,335 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,671 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,671 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —21,335 at $0.00 | filing |
| 28 Apr 2026filed 30 Apr 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 28 Apr 2026filed 30 Apr 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jun 2025filed 4 Jun 2025 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —113,246 at $0.00 | filing |
| 2 Jun 2025filed 4 Jun 2025 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —56,623 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $109K8,966 at $12.18 | filing |
| 1 Jan 2025filed 3 Jan 2025 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 1 Jan 2025filed 3 Jan 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | —3,500 | filing |
| 29 May 2024filed 31 May 2024 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —98,440 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —49,220 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —54,794 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —37,966 at $0.00 | filing |
| 8 Jan 2024filed 10 Jan 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $46K1,608 at $28.66 | filing |
| 8 Jan 2024filed 10 Jan 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $20K667 at $29.38 | filing |
| 3 Jan 2024filed 5 Jan 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $163K5,532 at $29.46 | filing |
| 1 Jan 2024filed 3 Jan 2024 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 1 Jan 2024filed 3 Jan 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | —3,500 | filing |
News
Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory Boardfinanznachrichten.de · 17 Sep 2026Contrasting Intellia Therapeutics (NASDAQ:NTLA) and BeyondSpring (NASDAQ:BYSI)NTLA · tickerreport.com · 19 Oct 2026Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)NTLA · themarketsdaily.com · 19 Oct 2026Intellia Therapeutics Names New CMO To Oversee Clinical And Regulatory FunctionsNTLA · rttnews.com · 13 Oct 2026
1 headline in the last 90 days name Laura Sepp-Lorenzino; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.